Skip to main content
Richard Becker, MD, Cardiology, Cincinnati, OH

RichardBeckerMD

Cardiology Cincinnati, OH

Interventional Cardiology, Vascular Medicine

chief, division of cardiovascular health and disease

Dr. Becker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Becker's full profile

Already have an account?

  • Office

    222 Piedmont Ave
    Cincinnati, OH 45219
    Phone+1 513-475-8521
    Fax+1 513-475-7480

Education & Training

  • UMass Chan Medical School
    UMass Chan Medical SchoolFellowship, Cardiovascular Disease, 1986 - 1989
  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationResidency, Internal Medicine, 1982 - 1985
  • University of Cincinnati College of Medicine
    University of Cincinnati College of MedicineClass of 1982, MD, Honors
  • University of Cincinnati
    University of CincinnatiM.Ed., Biochemistry/ Nutrition, 1978
  • University of Cincinnati
    University of CincinnatiB.A., Psychology, 1977

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 1984 - 2025
  • NC State Medical License
    NC State Medical License 2003 - 2014
  • MA State Medical License
    MA State Medical License 1986 - 2005
  • American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

  • World’s Most Influential Scientific Minds 2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
  • Daniel Drake Medal of Honor University of Cincinnati College of Medicine, 2011
  • Join now to see all

Publications & Presentations

PubMed

Journal Articles

  • Translation and Clinical Development of Antithrombotic Aptamers  
    Nimjee SM, Povsic TJ, Sullenger BA, Becker RC, Nucleic Acid Ther, 1/16/2016
  • Aspirin dosing in the primary and secondary prevention of cardiovascular events  
    Kim J, Becker RC, J Thomb Thrombolysis, 1/6/2016
  • The biochemistry, enzymology and pharmacology of non-vitamin K anticoagulant drug reversal agents and antidotes  
    Becker RC, J Thomb Thrombolysis, 1/1/2016
  • Join now to see all

Books/Book Chapters

  • Join now to see all

Abstracts/Posters

  • Factors Associated With Major Bleeding Events.
    Goodman SG, Wojdyla DM, Piccini JP, White, HD, Paolini JF, Nessel CC, Berkowitz SD, Mahaffey KW, Patel MR, Sherwood MW, Becker, RC, Halperin JL, Hacke W, Singer DE, Ha..., JACC, 1/11/2014
  • The Use Of Dual Antiplatlet Therapy And Patient Outcomes In Those Undergoing PCI In The Rocket AF Trial.
    Sherwood MW, Jones S, Cyr D, Becker R, Berkowitz S, Washam J, Breithardt G, Fox K, Halperin J, Hankey G, Singer D, Piccini J, Nessel C, Mahaffey K, Califf R, Hacke W, ..., JACC, 1/1/2014
  • Use And Outcomes Of Antiarrhythmic Therapy In Patients With Atrial Fibrillation Receiving Oral Anticoagulation: Results From The Rocket AF Trial.
    Steinberg B, Hellkamp A, Lokhnygina Y, Halperin J, Breithardt G, Passman R, Hankey G, Patel M, Becker R, Singer D, Berkowitz S, Nessel C, Mahaffey K, Fox K, Califf R, ..., JACC, 1/1/2014
  • Join now to see all

Lectures

  • Current Management of Myocardial Infarction 
    1/1/1999

Other

  • CD Rom Educational Service. 
    Becker RC, Up-To-Date
    1/1/2016
  • On behalf of The Executive Steering Committee and the ROCKET AF Study Investigators Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF TRIAL. 
    Wong KSL, Hu DY, Oomman A, Tan R-S, Patel MR, Singer DE, Breithardt G, Mahaffey KW, Becker RC, Califf R, Fox KAA, Berkowitz SD, Hacke W, Hankey GJ, Stroke Online
    http://stroke.ahajournals.org/content/early/2014/04/23/STROKEAHA.113.002968
    1/1/2014
  • Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease 
    Becker RC
    http://www.uptodate.com/contents/early-trials-of-platelet-glycoprotein-iib-iiia-receptor-inhibitors-
    UpToDate, Wolters Kluwer Health - 2012-07-02
  • Join now to see all

Authored Content

  • AHA Scientific Sessions 2022: “One World. Together for Science”November 2022
  • What Was Unique About This AHA Conference?November 2019
  • What Was Unique About This AHA Conference?November 2019

Press Mentions

  • A Long Haul with Long COVID-19
    A Long Haul with Long COVID-19November 25th, 2024
  • A Long Haul with Long COVID: Why Poor and Middle Income Americans Are Hit Hardest
    A Long Haul with Long COVID: Why Poor and Middle Income Americans Are Hit HardestNovember 24th, 2024
  • At 400 Million Patients and Counting, Long COVID Remains a Mysterious Affliction
    At 400 Million Patients and Counting, Long COVID Remains a Mysterious AfflictionNovember 24th, 2024
  • Join now to see all

Grant Support

  • U54,PPG,R01,U01NHLBIPresent

Research History

  • Translational and Discovery scienceAnti-thrombotic therapy drug development employing nucleic acids and cationic polymers.

Professional Memberships